319 related articles for article (PubMed ID: 26250656)
1. Does conditional approval for new oncology drugs in Europe lead to differences in health technology assessment decisions?
Lipska I; Hoekman J; McAuslane N; Leufkens HG; Hövels AM
Clin Pharmacol Ther; 2015 Nov; 98(5):489-91. PubMed ID: 26250656
[TBL] [Abstract][Full Text] [Related]
2. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
[TBL] [Abstract][Full Text] [Related]
3. New trends and challenges in the European regulation of innovative medicines.
Enzmann H
Regul Toxicol Pharmacol; 2016 Oct; 80():314-20. PubMed ID: 27237379
[TBL] [Abstract][Full Text] [Related]
4. Early Patient Access to Medicines: Health Technology Assessment Bodies Need to Catch Up with New Marketing Authorization Methods.
Leyens L; Brand A
Public Health Genomics; 2016; 19(3):187-91. PubMed ID: 27238553
[TBL] [Abstract][Full Text] [Related]
5. Weighing of Evidence by Health Technology Assessment Bodies: Retrospective Study of Reimbursement Recommendations for Conditionally Approved Drugs.
Vreman RA; Bouvy JC; Bloem LT; Hövels AM; Mantel-Teeuwisse AK; Leufkens HGM; Goettsch WG
Clin Pharmacol Ther; 2019 Mar; 105(3):684-691. PubMed ID: 30300938
[TBL] [Abstract][Full Text] [Related]
6. How do HTA agencies perceive conditional approval of medicines? Evidence from England, Scotland, France and Canada.
Mills M; Kanavos P
Health Policy; 2022 Nov; 126(11):1130-1143. PubMed ID: 36050193
[TBL] [Abstract][Full Text] [Related]
7. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
8. Interaction initiatives between regulatory, health technology assessment and coverage bodies, and industry.
Frønsdal K; Pichler F; Mardhani-Bayne L; Henshall C; Røttingen JA; Mørland B; Klemp M
Int J Technol Assess Health Care; 2012 Oct; 28(4):374-81. PubMed ID: 23062516
[TBL] [Abstract][Full Text] [Related]
9. Variation in Health Technology Assessment and Reimbursement Processes in Europe.
Akehurst RL; Abadie E; Renaudin N; Sarkozy F
Value Health; 2017 Jan; 20(1):67-76. PubMed ID: 28212972
[TBL] [Abstract][Full Text] [Related]
10. Health Technology Assessment in the Context of Adaptive Pathways for Medicines in Europe: Challenges and Opportunities.
Bouvy JC; Jonsson P; Longson C; Crabb N; Garner S
Clin Pharmacol Ther; 2016 Dec; 100(6):594-597. PubMed ID: 27530105
[TBL] [Abstract][Full Text] [Related]
11. HTA Barriers for Conditional Approval Drugs.
Mills M
Pharmacoeconomics; 2023 May; 41(5):529-545. PubMed ID: 36821044
[TBL] [Abstract][Full Text] [Related]
12. Conditional approval and approval under exceptional circumstances as regulatory instruments for stimulating responsible drug innovation in Europe.
Boon WP; Moors EH; Meijer A; Schellekens H
Clin Pharmacol Ther; 2010 Dec; 88(6):848-53. PubMed ID: 20962774
[TBL] [Abstract][Full Text] [Related]
13. Confirmatory versus explorative endpoint analysis: Decision-making on the basis of evidence available from market authorization and early benefit assessment for oncology drugs.
Niehaus I; Dintsios CM
Health Policy; 2018 Jun; 122(6):599-606. PubMed ID: 29605527
[TBL] [Abstract][Full Text] [Related]
14. Market access to new anticancer medicines for children and adolescents with cancer in Europe.
Schoot RA; Otth MA; Frederix GWJ; Leufkens HGM; Vassal G
Eur J Cancer; 2022 Apr; 165():146-153. PubMed ID: 35235871
[TBL] [Abstract][Full Text] [Related]
15. "Stick or Twist?" Negotiating Price and Data in an Era of Conditional Approval.
Gladwell D; Bullement A; Cowell W; Patterson K; Strong M
Value Health; 2020 Feb; 23(2):191-199. PubMed ID: 32113624
[TBL] [Abstract][Full Text] [Related]
16. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
17. Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe.
Vreman RA; Naci H; Goettsch WG; Mantel-Teeuwisse AK; Schneeweiss SG; Leufkens HGM; Kesselheim AS
Clin Pharmacol Ther; 2020 Aug; 108(2):350-357. PubMed ID: 32236959
[TBL] [Abstract][Full Text] [Related]
18. Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision-making of oncology medicines.
Kalf RRJ; Vreman RA; Delnoij DMJ; Bouvy ML; Goettsch WG
Pharmacol Res Perspect; 2021 Apr; 9(2):e00742. PubMed ID: 33749172
[TBL] [Abstract][Full Text] [Related]
19. Approval probabilities and regulatory review patterns for anticancer drugs in the European Union.
Hartmann M; Mayer-Nicolai C; Pfaff O
Crit Rev Oncol Hematol; 2013 Aug; 87(2):112-21. PubMed ID: 23433721
[TBL] [Abstract][Full Text] [Related]
20. The Role of Regulator-Imposed Post-Approval Studies in Health Technology Assessments for Conditionally Approved Drugs.
Vreman RA; Bloem LT; van Oirschot S; Hoekman J; van der Elst ME; Leufkens HG; Klungel OH; Goettsch WG; Mantel-Teeuwisse AK
Int J Health Policy Manag; 2022 May; 11(5):642-650. PubMed ID: 33131224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
